C4691001 C6

About this study

The Pfizer Clinical Research Unit Brussels is conducting a study of an investigational drug to treat complicated urinary tract infection.

Card Summary Component


The study is planned to last for approximately 10 weeks. Several examinations or procedures will be required in connection with the study:

  • A screening examination during which you will sign a COVID ICD and the study ICD
  • 1 treatment period organised of 9 days and 8 nights.
  • A follow-up phone call 

Each participant will have a follow-up phone call 28 to 35 days after administration of the last dose of study medicine.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.

Required overnight stay

8 nights

How long is the study?

Approximately 10 weeks

The length of the study includes the time from screening until the final follow-up call or study activity. There may be up to 28 days between screening and dosing


€ 2088.00 + € 240 for COVID-19 inconvenience fees

Participants in clinical trials at the PCRU receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.


Inhouse period from 12 to 20 April, FU phone call on 17 May

A detailed schedule will be handed over at screening.




0800.99.256 (フリーダイヤル:ベルギーから)、00800.フリーダイヤル:イギリス、フランス、ドイツ、オランダから)、+有料ダイヤル:上記以外の国から)に電話し、担当者に詳細をお問い合わせください。または、以下の登録フォームに入力してご送信ください。